Some of our services have changed due to COVID-19. Click here for details

11 February 2022

Moderna's COVID-19 booster vaccine trial targeting the Omicron Variant

Moderna is conducting a clinical trial, called the mRNA-1273-P305 clinical trial, on an investigational booster vaccine that may protect against the COVID-19 Omicron variant, and you may be eligible to take part. The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational mRNA-1273.529 booster vaccine compared to a booster dose of Moderna’s COVID-19 vaccine, Spikevax.

This trial is enrolling volunteers 16 years of age or older who are in good or stable health and have received two or three doses of the COVID-19 vaccine at least three months ago.

Participation in this trial lasts up to 13 months and includes phone calls and approximately 5-7 scheduled visits to the trial site. Participants will receive a single dose of either investigational booster vaccine, mRNA-1273.529, or the already authorized vaccine, Spikevax.

To learn more, please visit

Go back
Rate this page: